Last Updated: April 27, 2026

Claims for Patent: 10,912,836

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,912,836

Title:	Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer
Abstract:	The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastasis of cancer are additional aspects of the present invention.
Inventor(s):	Spiegel David A., McEnaney Patrick, Fitzgerald Kelly
Assignee:	YALE UNIVERSITY
Application Number:	US16180494
Patent Claims:

Details for Patent 10,912,836

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	10,912,836	2038-11-05
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	10,912,836	2038-11-05
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	June 21, 1989	10,912,836	2038-11-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	10,912,836	2038-11-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		10,912,836	2038-11-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		10,912,836	2038-11-05
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	June 04, 1986	10,912,836	2038-11-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,912,836

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
China	105407920	⤷ Start Trial
European Patent Office	2991677	⤷ Start Trial
Spain	2824026	⤷ Start Trial
Hong Kong	1222564	⤷ Start Trial
Japan	2016529204	⤷ Start Trial
Japan	6473138	⤷ Start Trial
United States of America	10117943	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.